Cluster 1 Calls – Health
Cluster 1 ‘Health’, which forms part of Pillar 2 of Horizon Europe, aims to address major European health challenges by supporting collaborative, interdisciplinary and transnational research and innovation projects. It helps to improve the health and well-being of populations, strengthen the resilience and sustainability of healthcare systems, and support the competitiveness of the European health industry.
Funding opportunities are organised around six main thematic areas:
- Health throughout life: health promotion and prevention.
- Environment and health: the effects of environmental and social factors on health.
- Diseases and reducing their burden: non-communicable diseases, rare diseases and infectious diseases.
- Healthcare systems: access to high-quality, sustainable and innovative care.
- Health tools and technologies: digital technologies, artificial intelligence, personalised medicine and new diagnostic tools.
- European health industry: innovation, competitiveness and the development of health solutions and products.
The Health Cluster also works in conjunction with the Cancer Mission and several European partnerships, notably on rare diseases, personalised medicine, antimicrobial resistance and the transformation of healthcare systems.
To identify opportunities relevant to their work, researchers can consult the 2026–2027 work programme, then find below the list of calls open in 2027 and their deadlines on the Health Cluster’s official calls page.
Call closing date: 17 February 2027
- HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities throughout the life course to support independent living and inclusion
- HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small-molecule antiviral therapeutics for pathogens with epidemic potential
- HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections caused by Flaviviruses
- HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections caused by Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against antimicrobial-resistant pathogens
- HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce the risks of adverse drug reactions resulting from the administration of multiple medications
- HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for the discovery and/or production of biologics
- HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials to advance innovative interventions for neurodegenerative diseases
- HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response using AI methodologies for chronic non-communicable diseases
- HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile point-of-care diagnostics
Call deadline: 16 September 2027
- HORIZON-HLTH-2027-03-TOOL-02: Advancing the bioprinting of living cells for regenerative medicine
- HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of cutting-edge artificial intelligence models for healthcare
*** The information and timetables published on the MER website are provided for guidance only, and the MER accepts no liability in the event of any omission or update to the dates announced. It is the responsibility of researchers to check the opening and closing dates of calls on the European Commission’s official websites.